<p><h1>Plasma-derived Factor VIII Market Analysis and Market Size: Global Industry Overview, Market Segmentation and Forecast (2023 to 2030)</h1></p><p><strong>Plasma-derived Factor VIII Market Analysis and Latest Trends</strong></p>
<p><p>Plasma-derived Factor VIII is a type of blood clotting protein that is extracted from human plasma. It is commonly used in the treatment of patients with Hemophilia A, a genetic disorder in which the blood is unable to clot properly. Plasma-derived Factor VIII helps to replace the missing protein in these patients and enables them to form blood clots.</p><p>The Plasma-derived Factor VIII market is expected to experience significant growth during the forecast period. One of the key factors driving this growth is the increasing prevalence of Hemophilia A worldwide. According to the World Federation of Hemophilia, it is estimated that approximately 1 in 5,000 males are born with Hemophilia A. This high prevalence of the disease is likely to drive the demand for Plasma-derived Factor VIII.</p><p>Furthermore, advancements in technology and the introduction of new products are expected to further boost the market growth. For instance, the development of long-acting Plasma-derived Factor VIII products that require less frequent administrations are gaining popularity among patients, as they offer increased convenience and improved patient compliance.</p><p>However, the market is also facing challenges such as the risk of infections associated with plasma-derived products and the availability of alternative therapies. These challenges may hinder market growth to some extent.</p><p>In terms of regions, North America currently holds the largest share in the Plasma-derived Factor VIII market, primarily due to the high prevalence of Hemophilia A in the region. However, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period, attributed to the increasing awareness about Hemophilia A and improving healthcare infrastructure in emerging economies like China and India.</p><p>Overall, the Plasma-derived Factor VIII market is anticipated to grow at a CAGR of 5.8% during the forecast period. Factors such as the increasing prevalence of Hemophilia A and advancements in technology are expected to drive market growth, while challenges such as the risk of infections and availability of alternatives may restrict the growth to some extent.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp; <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1358429">https://www.reliableresearchreports.com/enquiry/request-sample/1358429</a></strong></p>
<p>&nbsp;</p>
<p><strong>Plasma-derived Factor VIII Major Market Players</strong></p>
<p><p>The plasma-derived Factor VIII market is highly competitive, with several key players dominating the industry. These players include Takeda, Octapharma, CSL, Grifols, GreenCross, Kedrion, BPL, Hualan Bio, and RAAS. Here, we will focus on Takeda, CSL, and Grifols, providing an overview of their past history, market growth, market size, and sales revenue.</p><p>Takeda is one of the leading global pharmaceutical companies, specializing in the development and production of innovative medicines. It has a long history of more than 230 years and has been involved in the plasma-derived Factor VIII market for several decades. Takeda's market growth has been significant due to its strong product portfolio and continuous investment in research and development. The company's market size in the plasma-derived Factor VIII market is estimated to be substantial, with a global presence and a large customer base. Takeda has reported total sales revenue of approximately $17.4 billion in the fiscal year 2020.</p><p>CSL is another major player in the plasma-derived Factor VIII market, known for its expertise in plasma protein biotherapeutics. The company has a rich history of over 100 years and has consistently been at the forefront of innovation in the industry. CSL's market growth has been impressive, driven by its commitment to patient care, scientific advancements, and strategic acquisitions. The company operates globally and has a considerable market size in the plasma-derived Factor VIII market. CSL reported sales revenue of approximately $9.8 billion for the fiscal year 2020.</p><p>Grifols is a Spanish pharmaceutical and healthcare company that has a strong presence in the plasma-derived Factor VIII market. With over 75 years of experience, Grifols has become a global leader in plasma-derived medicines. The company has achieved significant market growth through strategic partnerships and acquisitions, expanding its product portfolio and global footprint. Grifols has a substantial market size in the plasma-derived Factor VIII market, serving patients worldwide. The company's sales revenue reached approximately $5.3 billion in the fiscal year 2020.</p><p>The sales revenue of the other mentioned companies, including Octapharma, GreenCross, Kedrion, BPL, Hualan Bio, and RAAS, vary based on market factors, geographical presence, and product offerings. However, these companies also hold a notable market share within the plasma-derived Factor VIII market, contributing to the overall competitiveness of the industry.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Plasma-derived Factor VIII Manufacturers?</strong></p>
<p><p>The plasma-derived Factor VIII market has been witnessing a steady growth over the past few years, and this trend is expected to continue in the future. Factors driving market growth include the rising prevalence of hemophilia A, increasing demand for effective treatments, and advancements in plasma fractionation technologies. Additionally, the growing awareness regarding the benefits of plasma-derived Factor VIII products among patients and healthcare professionals is also contributing to market growth. Looking ahead, the market is anticipated to witness further expansion, driven by the rising demand for hemophilia treatment options, particularly in developing countries where access to advanced therapies is improving.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report: <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1358429">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1358429</a></strong></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Plasma-derived Factor VIII Market Analysis by types is segmented into:</strong></p>
<p><ul><li>200IU</li><li>250IU</li></ul></p>
<p><p>The plasma-derived Factor VIII market includes two types: 200IU and 250IU. The first type refers to products with a concentration of 200 International Units (IU) of Factor VIII per milliliter (ml) of plasma-derived solution. Similarly, the second type refers to products with a concentration of 250IU of Factor VIII per ml of plasma-derived solution. These different concentration levels cater to specific patient needs, allowing healthcare professionals to select the appropriate dosage based on the severity of the condition and individual patient requirements.</p></p>
<p><strong>Purchase this Report:&nbsp;<a href="https://www.reliableresearchreports.com/purchase/1358429">https://www.reliableresearchreports.com/purchase/1358429</a></strong></p>
<p>&nbsp;</p>
<p><strong>The Plasma-derived Factor VIII Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital</li><li>Pharmacy</li></ul></p>
<p><p>The plasma-derived Factor VIII market application in hospitals refers to the usage and demand for this blood clotting protein in medical settings to treat patients with hemophilia A. Hospitals require a steady supply of Factor VIII to administer in emergency situations or during surgical procedures to control bleeding. Similarly, the pharmacy market also plays a crucial role in the distribution of Factor VIII to patients for the management of their condition. Both hospital and pharmacy markets aim to ensure accessibility and availability of this essential medication for individuals with hemophilia A.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Plasma-derived Factor VIII Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The plasma-derived factor VIII market has witnessed significant growth across various regions such as North America (NA), Asia Pacific (APAC), Europe, the United States (USA), and China. North America holds a dominant position in the market due to a high prevalence of bleeding disorders and increased adoption of advanced treatment options. Similarly, Europe exhibits substantial growth potential, driven by a well-established healthcare infrastructure. APAC, especially China, presents lucrative opportunities for market players due to growing awareness about bleeding disorders and improving healthcare facilities. Overall, the North American region is expected to dominate the market with a projected market share of approximately 40%, followed by Europe (30%), APAC (20%), and the USA and China (5% each).</p></p>
<p><strong>Purchase this Report: <a href="https://www.reliableresearchreports.com/purchase/1358429">https://www.reliableresearchreports.com/purchase/1358429</a></strong></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;<a href="https://www.reliableresearchreports.com/enquiry/request-sample/1358429">https://www.reliableresearchreports.com/enquiry/request-sample/1358429</a></strong></p>
<p><strong></strong></p>
<p><p><a href="https://www.linkedin.com/pulse/freezer-meal-market-research-report-provides-thorough-industry-2f1se/">Freezer Meal Market</a></p><p><a href="https://medium.com/@marvinhug741/cut-flower-packaging-market-size-growth-forecast-2023-2030-96bf72e36444">Cut Flower Packaging Market</a></p><p><a href="https://www.linkedin.com/pulse/nonfat-dried-milk-market-size-growth-forecast-from-2023-ltnee/">Nonfat Dried Milk Market</a></p><p><a href="https://www.linkedin.com/pulse/peanut-paste-market-research-report-unlocks-analysis-financial-ygspe/">Peanut Paste Market</a></p><p><a href="https://medium.com/@claudekunze/lte-testing-equipment-market-size-growth-forecast-2023-2030-1bd9ea70ba75">LTE Testing Equipment Market</a></p></p>